Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;21(1):34-40.
doi: 10.1007/BF02913064.

Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate

T Malati  1 , G Rajani Kumari, P V L N Murthy, Ch Ram Reddy, B Surya Prakash
Affiliations

Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate

T Malati et al. Indian J Clin Biochem. 2006 Mar.

Abstract

Prostate Specific Antigen (PSA) has emerged as the most applicable and important tumor marker for carcinoma prostate. In the present study PSA was determined in serum of healthy subjects, patients of benign prostate hypertrophy (BPH) and Carcinoma Prostate (Ca-P) to evaluate its diagnostic efficiency in day to day management of prostate cancer patients and in differentiating patients of early prostate cancer from those with BPH. Receiver operating characteristic curve (ROC) revealed 2 ng/ml and 10 ng/ml cut off serum PSA level for BPH and untreated carcinoma prostate patients (Ca-P). An extremely significant increase (P<0.0001) was observed in mean PSA concentration in BPH patients and adenocarcinoma prostate patients when compared to healthy males. Clinical relevance of PSA was highlighted by a case study of cancer patient prior to any therapy till death.

Keywords: BPH; Carcinoma Prostate; Total PSA; long term case study.

PubMed Disclaimer

References

    1. Pienta, Esper Risk factors for prostate cancer. Ann Inter Med. 1993;118:793–803. - PubMed
    1. Morgan T. O., Steven J., Jacobsen W. F., McCarthy D. J., Jacobson D. G., McLeod, Moul J. W. Age Specific reference ranges for serum prostate specific Antigen in Black Men. New Engl. J. Med. 1996;335(5):304–310. doi: 10.1056/NEJM199608013350502. - DOI - PubMed
    1. Kramer B. S., Brown M. L., Prorok P. C., Potosky A., Gohagan J. K. Prostate caner screening: what we know and what we need to know. Ann. Intern. Med. 1993;119:914–923. - PubMed
    1. Malati T., Rajani Kumari G. Racial and Ethnic variation of Prostate Specific Antigen in global population: Age specific reference intervals for serum Prostate Specific Antigen in healthy South Indian males. Ind. J. Clin. Biochem. 2004;19(1):32–137. doi: 10.1007/BF02872408. - DOI - PMC - PubMed
    1. Rajani Kumari G., Malati T. Stability of total and free prostate specific antigen in serum samples at different storage conditions. Ind. J. Clin. Biochem. 2004;19(2):10–13. doi: 10.1007/BF02894250. - DOI - PMC - PubMed

LinkOut - more resources